Mayne Pharma Group Limited (MYX.AX) Stock

MYX.AX logo

Mayne Pharma Group Limited

MYX.AXAustralia
Healthcare

Company profile

Its largest business segment, Women's Health, brought in 44% of segment revenue in fiscal year 2025; United States was the largest region with 83%. Mayne Pharma Group reports about 363 full-time employees.

Figures from company filings; latest fiscal year ended June 30, 2025.

About Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Largest shareholders

  • Cable Car Capital LP9.82%
  • Bruce Mathieson6.462 %6.46%
  • Rubric Capital Management LP5.32%
  • Trium Capital LLP4.99%
  • Ubs Group AG3.94%

Share of the company, as of September 25, 2026

Leadership

  • Aaron Gray — Chief Executive Officer
  • Daniel Moore — President of DistributeRx
  • Griffin D. Buchanan — Chief Financial Officer
  • Frank Casty M.D. — Executive VP, Global Head of R&D and Chief Medical Officer
  • Kimberly Parker J.D. — Executive VP & General Counsel

What is Mayne Pharma Group's largest business segment?

Women's Health, with 178.37 million AUD or 44% of segment revenue in fiscal year 2025. Next: Dermatology (38%) and International (19%).

Where does Mayne Pharma Group make most of its revenue?

United States: 83% of revenue by region in fiscal year 2025, followed by Australia and New Zealand (10%).

What companies are similar to Mayne Pharma Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include CSL Limited (CSL.AX), BTC Health Limited (BTC.AX), Acrux Limited (ACR.AX), Argent BioPharma Limited (RGT.AX).

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees363
Founded1845
IPO DateJun 29, 2007
IPO StatusPublic
HeadquartersSalisbury South, Australia
FoundersScott Richards
ExchangeASX
TimezoneAustralia/Sydney (AEDT)

Contact & Links

Address
1538 Main North Road, Salisbury South, 5106
Phone
61 8 8209 2666
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Mayne Pharma Group Limited (MYX.AX)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/MYX.AX

LinkedInLinkedInXXYouTubeYouTube